Asthma drug helps patients with skin disorder

April 7, 2017, Charité - Universitätsmedizin Berlin
Obstruction of the lumen of a bronchiole by mucoid exudate, goblet cell metaplasia, and epithelial basement membrane thickening in a person with asthma. Credit: Yale Rosen/Wikipedia/CC BY-SA 2.0

Patients who develop itchy wheals in response to cold or friction benefit from treatment with omalizumab, a drug normally used to treat asthma. Two separate clinical studies, conducted by researchers from Charité - Universitätsmedizin Berlin, have shown the drug's active substance to be highly effective against different types of urticaria (hives). Results from these studies have been published in the current edition of the Journal of Allergy and Clinical Immunology.

Cold urticaria and symptomatic dermographism are different forms of inducible urticaria, a skin disease characterized by itchy wheals, which develop in response to such as cold or friction. Patients with cold urticaria, for instance, cannot go swimming in the sea without risking an allergic reaction that may lead to shock; similarly, they cannot hold items colder than room temperature. In patients with symptomatic dermographism, even gentle friction, such as that caused by clothing or physical contact, can result in severe itching. People affected by the disorder often experience a reduced quality of life, and are forced to make adjustments to both their social and working lives.

As part of two investigator-initiated, multicenter, randomized, placebo-controlled trials, researchers from the Department of Dermatology, Venereology and Allergology used the monoclonal antibody omalizumab to treat two different patient groups (61 patients with symptomatic dermographism and 31 patients with cold urticaria) for a period of three months. In order to test the efficacy of treatment, researchers used objective measurement techniques to determine provocation threshold values for all study participants. Initial measurements were carried out prior to the first administration of the drug. Once the second dose had been administered, measurements were repeated at four-weekly intervals, followed by a final measurement two weeks after the final dose. Results showed that treatment with omalizumab led to significant improvements in symptoms in both groups of patients, and prevented symptoms in nearly half of all patients with cold urticaria and symptomatic dermographism, even after exposure to the relevant stimuli.

"Our results show that patients with severe forms of physical urticaria can benefit from treatment with omalizumab," says Prof. Dr. Martin Metz. The drug is currently only licensed for use in patients with traditional hives, known as . "However, given our data on the drug's effectiveness in with cold urticaria and symptomatic dermographism, we are hopeful that the drug will be made available to both of these ," adds Prof. Metz.

Explore further: Omalizumab effective for chronic spontaneous urticaria

More information: Martin Metz et al, Omalizumab is Effective in Cold Urticaria - Results of a Randomized, Placebo Controlled Trial, Journal of Allergy and Clinical Immunology (2017). DOI: 10.1016/j.jaci.2017.01.043

Related Stories

Omalizumab effective for chronic spontaneous urticaria

March 31, 2016
(HealthDay)—Omalizumab is effective in patients with moderate-to-severe chronic spontaneous urticaria (CSU) symptoms and angioedema unresponsive to high doses of antihistamine treatment, according to a study published online ...

Doxycycline helps one-third of chronic cold urticaria patients

July 11, 2016
(HealthDay)—Just over one-third of chronic cold urticaria patients benefit from treatment with doxycycline, according to a research letter published online June 25 in the British Journal of Dermatology.

A step forward in the treatment of chronic urticaria

March 20, 2013
An international study involving dermatologists from the Hospital del Mar and Spanish subjects has concluded that a drug normally used to treat severe bronchial asthma caused by allergies (Omalizumab) rapidly eliminates the ...

Tolerance develops in NSAID-induced urticaria/angioedema

March 4, 2017
(HealthDay)—Patients with nonsteroidal anti-inflammatory drug (NSAID)-induced urticaria/angioedema (NIUA) may develop tolerance to NSAIDs over time, according to a study published online Feb. 22 in Allergy.

Aspirin may exacerbate chronic urticaria in children

November 10, 2014
(HealthDay)—In some children with chronic spontaneous urticaria (CSU), exacerbations may be caused by hypersensitivity to aspirin, according to research published online Oct. 29 in Allergy.

Which comes first: Self-reported penicillin allergy or chronic hives?

February 3, 2016
People who have self-reported penicillin allergy may have a three times greater chance of suffering from chronic hives. And people who have chronic hives tend to self-report penicillin allergy at a three times greater rate ...

Recommended for you

New study shows how gut immune cells are kept in control

June 22, 2018
Every day, the human gut works on a fine-tuned balance that ensures the retention of essential nutrients while preventing infection by potential armful microbes. Contributing to this surveillance system is a specialised group ...

Human immune 'trigger' map paves way for better treatments

June 21, 2018
A discovery about how human cells are 'triggered' to undergo an inflammatory type of cell death could have implications for treating cancer, stroke and tissue injury, and immune disorders.

Our intestinal microbiome influences metabolism—through the immune system

June 21, 2018
Research tells us that the commensal or "good" bacteria that inhabit our intestines help to regulate our metabolism. A new study in fruit flies, published June 21 in Cell Metabolism, shows one surprising way they do this.

Fetal T cells are first responders to infection in adults

June 20, 2018
Cornell University researchers have discovered there is a division of labor among immune cells that fight invading pathogens in the body.

How a thieving transcription factor dominates the genome

June 20, 2018
One powerful DNA-binding protein, the transcription factor PU.1, steals away other transcription factors and recruits them for its own purposes, effectively dominating gene regulation in developing immune cells, according ...

Severe stress may send immune system into overdrive

June 19, 2018
(HealthDay)—Trauma or intense stress may up your odds of developing an autoimmune disease, a new study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.